1p杂合性缺失是少枝胶质瘤最常见的分子生物学特征，并与肿瘤的化疗敏感性和预后有关，但其相关机制仍然不清；现有证据表明1p染色体上存在着大量与肿瘤转化相关的长链非编码RNA（lncRNA）。因此，我们推测1p染色体上可能隐藏有某些lncRNA或基因是少枝胶质瘤恶性转化所必须的，这些特异性表达的lncRNA可以作为胶质瘤潜在的预测和/或治疗靶点。本研究通过对少枝胶质瘤中替莫唑胺（TMZ）耐药性lncRNA表达谱的分析，筛选定位于1p染色体的与TMZ耐药相关的lncRNA；确定该lncRNA在TMZ药物处理后是原发性还是继发响应性的高表达；分析研究该lncRNA在胶质瘤恶性进展中的分子机制及其临床意义。本课题结合胶质瘤体外药敏和肿瘤1p缺失结果，首次全面性分析胶质瘤中1p上的转录本信息，寻找化疗耐药相关lncRNA，有望进一步了解胶质瘤发生发展和化疗耐药的分子机制。

1p LOH(loss of heterozygosity), as the most common molecular biological characteristics of oligodendroglioma, may be contributed to the chemosensitivity and prognosis of tumors. However, underlying mechanisms are still unclear. Now available evidence indicate that a large number of lncRNA associated with tumor transforming exist in chromosome 1p. So we suppose that some lncRNA or genes required by oligodendrogliomas’ malignant transformation must hide in chromosome 1p and these specifically expressive lncRNA can be used as potential prediction and/or treatment targets of glioma. In this study, through analyzing the lncRNA expression profile of oligodendroglioma associated with temozolomide(TMZ) chemoresistance, we will screen out the lncRNA located in chromosome 1p, which are associated with TMZ chemoresistance; determine that high expression of lncRNA whether primary or secondary response; explore the molecular mechanisms and clinical significance of that lncRNA in the malignant progression of glioma. For the first time, we comprehensively study the transcript information of chromosome 1p in gliomas; seek lncRNA associated with chemoresistance; furtherly understand the molecular mechanisms of tumor progression and chemoresistance of glioma, through combining results of chemosensitivity in vitro and 1p status of oligodendrogliomas.